Cipla 

Cipla Limited is a Mumbai-headquartered global pharmaceutical company whose published purpose is Caring For Life. For nine decades it has treated high-quality, affordable medicines as an industrial problem, not a charity slogan: incorporate in 1935, grow a portfolio that now exceeds 1,500 products across more than 50 dosage forms, and take that portfolio into 74 markets. India, South Africa, the United States and a cluster of emerging markets are the operating theatres. About 30,000 people sit behind a reported turnover of $3.26 billion. Those figures belong on cipla.com and in exchange filings; they are cited here only as the company’s own scale markers. The product machine is deliberately wide. Tablets, respules, inhalers and injections sit alongside respiratory franchises, active pharmaceutical ingredients, generics, oncology and HIV. In 2001 Cipla put a triple antiretroviral combination into Africa at under a dollar a day—an episode the company still uses as proof that access and chemistry can occupy the same sentence. Respiratory devices and APIs remain core because they are hard to copy well and because they travel across income levels. None of this is medical advice. Labels, licensed indications and a physician decide what a patient takes. The operating credo is written as five hyphenated claims: Purpose-Inspired, Responsibility-Centered, Innovation-Driven, Integrity and Trust-Anchored, Excellence-Focused. The language is corporate, but it maps onto a real manufacturing and regulatory burden: plants that must satisfy Indian, US and other inspectors, a pipeline that has to refresh a 1,500-SKU catalogue, and a commercial model that cannot treat Africa or emerging Asia as residual markets. Caring For Life is the public name for that burden. Official channels on Facebook, Instagram, X, LinkedIn and YouTube carry brand films, results commentary, HIV and respiratory history, and careers colour. They are not adverse-event desks, pharmacy counters or places to share prescriptions or personal health data. Product complaints and safety reports belong on the contact routes Cipla publishes, including the country helplines and drugsafety addresses on the corporate site. Follow the pages for the operating company: a 90-year Indian manufacturer that still presents affordable, high-quality medicine as the point of the enterprise, then verify every number, indication and plant claim at the source.